[go: up one dir, main page]

JP2015524421A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524421A5
JP2015524421A5 JP2015523548A JP2015523548A JP2015524421A5 JP 2015524421 A5 JP2015524421 A5 JP 2015524421A5 JP 2015523548 A JP2015523548 A JP 2015523548A JP 2015523548 A JP2015523548 A JP 2015523548A JP 2015524421 A5 JP2015524421 A5 JP 2015524421A5
Authority
JP
Japan
Prior art keywords
composition
dengue
use according
serotype
dengue virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015523548A
Other languages
English (en)
Other versions
JP2015524421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065667 external-priority patent/WO2014016360A1/en
Publication of JP2015524421A publication Critical patent/JP2015524421A/ja
Publication of JP2015524421A5 publication Critical patent/JP2015524421A5/ja
Ceased legal-status Critical Current

Links

Claims (18)

  1. デング病に対するヒト対象の保護方法に使用するためのワクチン組成物であって、以下:
    (i) 以下からなる群から選択されるデング抗原:
    (a) 弱毒化生デングウイルス;
    (b) 不活化デングウイルス;
    (c) 弱毒化生、または不活化キメラデングウイルス;
    (d) デングウイルス様粒子 (VLP); および
    (e) (a)〜(d)の2つ以上の組合せ;
    または
    (ii) ヒト細胞において、デングVLPであるデング抗原を発現させることのできる核酸構築物またはウイルスベクター
    を含む、ワクチン組成物。
  2. 該対象がデング免疫性である、請求項1記載の、使用するための組成物。
  3. 該ヒトが9〜16歳である、請求項1または2記載の、使用するための組成物。
  4. 該ヒトが9〜60歳である、請求項1または2記載の、使用するための組成物。
  5. 該ヒトが9〜45歳である、請求項1または2記載の、使用するための組成物。
  6. 該対象がデング流行地域に居住している、請求項1〜5のいずれか記載の、使用するための組成物。
  7. 該デング病が、血清型1、血清型3または血清型4のデングウイルスにより引き起こされる、請求項1〜のいずれか記載の方法に使用するための組成物。
  8. 該方法が該組成物を3回以上投与することを含む、請求項1〜7のいずれか記載の、使用するための組成物。
  9. 該方法が、1回目、2回目および3回目に投与することを含み、2回目の投与を1回目の投与から約6ヶ月後に行い、3回目の投与を1回目の投与の約12ヶ月後に行う、請求項6〜8のいずれか記載の、使用するための組成物。
  10. 該組成物が血清型1のデング抗原、血清型2のデング抗原、血清型3のデング抗原および血清型4のデング抗原を含む、請求項1〜のいずれか記載の、使用するための組成物。
  11. 該組成物が、弱毒化生デングウイルスまたは弱毒化生キメラデングウイルスを含む、請求項1〜10のいずれか記載の、使用するための組成物。
  12. 弱毒化生キメラデングウイルスを含む、請求項1〜11のいずれか記載の、使用するための組成物。
  13. 該キメラデングウイルスが、デングウイルス由来の1つ以上の蛋白質と、異なるフラビウイルス由来の1つ以上の蛋白質とを含む、請求項1〜12のいずれか記載の、使用するための組成物。
  14. 異なるフラビウイルスが、黄熱ウイルスである、請求項13記載の、使用するための組成物。
  15. 該キメラデングウイルスが、prM−E配列がデングウイルスのprM−E配列で置換された、黄熱ウイルスのゲノムを含む、請求項10〜14のいずれか記載の、使用するための組成物。
  16. 少なくとも1つの血清型デングウイルスが、約10〜約10 CCID50の量で存在する、請求項10〜15のいずれか記載の、使用するための組成物。
  17. 4つ全ての血清型のデングウイルスを含み、各血清型が約10〜約10 CCID50の量で存在する、請求項15記載の、使用するための組成物。
  18. 4つ全ての血清型のデングウイルスを含み、各血清型が約10 CCID 50 の量で存在する、請求項16記載の、使用するための組成物。
JP2015523548A 2012-07-24 2013-07-24 ワクチン組成物 Ceased JP2015524421A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305907.3 2012-07-24
EP12305907 2012-07-24
EP12305912 2012-07-25
EP12305912.3 2012-07-25
PCT/EP2013/065667 WO2014016360A1 (en) 2012-07-24 2013-07-24 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019071529A Division JP6830118B2 (ja) 2012-07-24 2019-04-03 ワクチン組成物

Publications (2)

Publication Number Publication Date
JP2015524421A JP2015524421A (ja) 2015-08-24
JP2015524421A5 true JP2015524421A5 (ja) 2016-09-08

Family

ID=48875047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015523548A Ceased JP2015524421A (ja) 2012-07-24 2013-07-24 ワクチン組成物
JP2019071529A Active JP6830118B2 (ja) 2012-07-24 2019-04-03 ワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019071529A Active JP6830118B2 (ja) 2012-07-24 2019-04-03 ワクチン組成物

Country Status (12)

Country Link
US (2) US20150196631A1 (ja)
EP (2) EP3932422A1 (ja)
JP (2) JP2015524421A (ja)
KR (2) KR20200067938A (ja)
CN (1) CN104812407B (ja)
AU (1) AU2013295014B2 (ja)
CA (1) CA2878682A1 (ja)
MX (2) MX381497B (ja)
MY (2) MY197723A (ja)
PH (1) PH12014502840B1 (ja)
SG (2) SG11201500412TA (ja)
WO (1) WO2014016360A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1212905A1 (zh) * 2012-07-24 2016-06-24 Sanofi Pasteur 用於防止登革热病毒感染的疫苗组合物
PH12015502120B1 (en) 2013-03-15 2024-02-16 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
US10487120B2 (en) * 2015-02-09 2019-11-26 Academia Sinica Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP3147294B1 (en) * 2015-09-24 2020-04-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
CA3005814C (en) * 2015-11-27 2022-09-27 The Chemo-Sero-Therapeutic Research Institute Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
MX2018012459A (es) * 2016-04-13 2019-06-06 Takeda Vaccines Inc Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) * 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
WO2019113285A2 (en) 2017-12-06 2019-06-13 Emory University Zika vaccines and methods of use
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN116334070A (zh) * 2023-02-15 2023-06-27 天津大学 融合蛋白的应用和细胞融合的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422A (en) 1848-02-01 Spark-arrester
US109A (en) 1836-12-15 Erawijtg
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
PT1625852E (pt) 1997-02-28 2010-08-27 Acambis Inc Vacinas quiméricas de flavivírus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
EP1165128A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-2 virus vaccine
US6528065B1 (en) 1999-03-26 2003-03-04 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-3 virus vaccine
WO2000057908A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research, Department Of The Army Attenuated dengue-1 virus vaccine
WO2000057910A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1263965B1 (en) 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
PT1159968E (pt) 2000-05-30 2008-11-20 Univ Mahidol Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA3060687C (en) 2001-05-22 2021-05-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
JP2005501532A (ja) 2001-06-01 2005-01-20 アカンビス インコーポレーティッド キメラフラビウイルスベクター
KR101194818B1 (ko) * 2002-01-15 2012-10-25 사노피 파스테르 바이오로직스, 엘엘씨 플라비바이러스 백신
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
BRPI0618850A2 (pt) * 2005-11-21 2011-09-13 Sanofi Pasteur Ltd formulações de estabilização para vìrus recombinantes
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition

Similar Documents

Publication Publication Date Title
JP2015524421A5 (ja)
Trovato et al. Viral emerging diseases: challenges in developing vaccination strategies
Yong et al. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus
JP2017526689A5 (ja)
Belete A review on Promising vaccine development progress for COVID-19 disease
Khetarpal et al. Dengue fever: causes, complications, and vaccine strategies
JP2019151636A5 (ja)
JP2015524422A5 (ja)
Li et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates
DeFilippis Chikungunya virus vaccines: platforms, progress, and challenges
Golden et al. The strategic use of novel smallpox vaccines in the post-eradication world
Huang et al. Vaccine development for mosquito-borne viral diseases
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
Torres-Ruesta et al. Insights into antibody-mediated alphavirus immunity and vaccine development landscape
Plummer et al. Mouse models for dengue vaccines and antivirals
Norrby Outlook for a dengue vaccine
Zhang et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71
Kim et al. Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus
Medina et al. Virulence and immune evasion strategies of FMDV: implications for vaccine design
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
Patel et al. Understanding COVID-19 vaccines and their development
WO2017116177A3 (ko) 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물
JP2020536107A5 (ja)
Murala et al. Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2